In brief, SOLOIST-WHF is significant and impacts clinical practice as it was the first trial to show that SGLT2/1 inhibitors are effective and safe for use in those with T2DM, reduced or preserved ejection fraction heart failure, and recent heart failure admission. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.